Clinical Trials Logo

Clinical Trial Summary

Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of the sweat glands. Current therapies have limited effectiveness, significant side effects, and can be invasive and costly. Sofpironium bromide (BBI-4000) is a novel soft-drug in development for the topical treatment of hyperhidrosis. This Phase 3 study will assess the safety and efficacy of sofpironium bromide, 15% gel versus vehicle (2 treatment arms), applied for the treatment of axillary hyperhidrosis.


Clinical Trial Description

This is a multicenter, randomized, double-blind, vehicle-controlled study to evaluate the safety and efficacy of topically applied sofpironium bromide, 15% gel in subjects with axillary hyperhidrosis. Safety will be assessed through collection of vital signs, adverse events, local skin responses, hematology, serum chemistry laboratory testing and urinalysis. A maximum of 350 subjects will be randomized to receive either sofpironium bromide gel, 15% or vehicle. Adverse events, vital signs, and local tolerability assessments will be collected at visits across the study. Urine pregnancy tests will be taken throughout the course of the study for women of child bearing potential. Blood and urine samples will be collected and analyzed for routine hematology, chemistry, and urinalysis parameters at specified visits. Patient-reported outcome assessments will be recorded during the study at predefined time points. The study will be comprised of a total of 13 scheduled visits to take place over approximately 11 to 15 weeks. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03948646
Study type Interventional
Source Botanix Pharmaceuticals
Contact
Status Completed
Phase Phase 3
Start date December 4, 2020
Completion date August 13, 2021

See also
  Status Clinical Trial Phase
Completed NCT04546438 - Patient Satisfaction and Safety of Miradry Treatment for Axillary Hyperhidrosis N/A
Completed NCT03836287 - Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301) Phase 3
Enrolling by invitation NCT02105753 - Tx Axillary Hyperhidrosis 1210nm Diode Laser N/A
Withdrawn NCT05546710 - miraDry Post Market Tumescent Anesthesia Study N/A
Active, not recruiting NCT02295891 - Miradry Treatment for Focal Axillary Hyperhidrosis N/A
Completed NCT01118429 - Use of Oxybutynin to Treat Axillary Hyperhidrosis N/A
Completed NCT01091129 - Clinical Evaluation of the miraDry System in Subjects With Hyperhidrosis N/A
Completed NCT01274611 - Botox and Suction-Curettage for Treatment of Excessive Underarm Sweating (Axillary Hyperhidrosis) N/A
Completed NCT03320096 - Evaluation of the Ulthera System for Treating Axillary Hyperhidrosis N/A
Completed NCT00735293 - VASER Treatment of Axillary Hyperhidrosis/Bromidrosis Phase 4